Pharmaceutical CEOs are on notice about sky-high drug prices as President Donald Trump demands a recalibration of what ...

AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was “rapidly ...

AstraZeneca’s CEO said the company has proposed U.S. price cuts to some drugs, while Doximity enters competitive AI scribing ...

AstraZeneca has proposed price cuts to its drugs in the United States, its CEO said on Tuesday, days after unveiling a $50 ...

It plans to invest $50 billion in the US over five years, including building its largest-ever manufacturing facility in ...

In an earnings call on July 29th, in which the company reported a 13% increase in half-year profits, he said about Britain ...

With its latest $50 billion U.S. manufacturing investment and record U.S. growth, is British AstraZeneca looking at itself as ...

Plus: All the news and watercooler chat from Fortune.

Pascal Soriot's comments came during AstraZeneca's Q2 earnings call in regard to President Donald Trump’s newly announced ...

The pharmaceutical industry has long protested the idea of globally linked drug prices as a threat to years of U.S. dominance ...

Markets reflect a widespread belief that the US president always chickens out on trade measures. AstraZeneca’s plan to invest ...

Speaking from Astra's offices in New York, Sir Pascal Soriot (pictured) said it was 'global', but it was 'very much rooted ...